COVID-19 感染在多发性硬化症（MS）患者中的流行情况：系统评价和荟萃分析。
The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
机构信息
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
出版信息
Neurol Sci. 2021 Aug;42(8):3093-3099. doi: 10.1007/s10072-021-05373-1. Epub 2021 Jun 7.
BACKGROUND
The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to estimate the pooled prevalence of COVID-19 in patients with MS.
METHODS
Two independent researchers independently searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (((coronavirus OR Wuhan coronavirus OR novel coronavirus OR coronavirus disease OR COVID-19 OR 2019 novel coronavirus infection OR 2019-nCOV OR severe acute respiratory syndrome coronavirus 2 OR SARS-CoV-2) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating).
RESULTS
We found 1466 articles by literature search, and after deleting duplicates, 1029 remained. Twelve articles remained for meta-analysis. Totally, 101,462 patients were evaluated and the total number of possible/confirmed cases was 1394. Mean age ranged from 35 to 54 years. Totally, 49 patients died. The pooled prevalence of suspected COVID-19 in MS patients was 4% (95% CI: 3-4%) (I = 98.5%, P < 0.001). The pooled prevalence of hospitalization in infected cases was 10% (95% CI: 7-12%) (I = 95.6%, P < 0.001). The pooled prevalence of death in hospitalized cases was 4% (95% CI: 1-6%) (I = 82.4%, P < 0.001).
CONCLUSION
Hospitalization rate is higher among MS patients based on COVID-19 infection while the pooled infection rate is estimated as 4%.
背景
不同国家开展的研究中，COVID-19 的流行情况有所不同。本系统评价和荟萃分析旨在估计 COVID-19 在多发性硬化症患者中的总体患病率。
方法
两位独立的研究人员分别独立检索了 PubMed、Scopus、EMBASE、Web of Science 和谷歌学术以及灰色文献，检索时间截至 2021 年 4 月。检索策略包括主题词和文本词，如（（（冠状病毒或武汉冠状病毒或新型冠状病毒或冠状病毒病或 COVID-19 或 2019 年新型冠状病毒感染或 2019-nCOV 或严重急性呼吸综合征冠状病毒 2 或 SARS-CoV-2）和（多发性硬化症或多发性硬化症）或多发性硬化症）或多发性硬化症，播散性）或播散性硬化症）或 MS（多发性硬化症））或多发性硬化症，急性暴发性）。
结果
通过文献检索，我们发现了 1466 篇文章，删除重复项后，还剩 1029 篇。有 12 篇文章进行了荟萃分析。总共评估了 101462 名患者，可能/确诊病例总数为 1394 例。平均年龄在 35 至 54 岁之间。总共有 49 名患者死亡。多发性硬化症患者疑似 COVID-19 的总体患病率为 4%（95%CI：3-4%）（I=98.5%，P<0.001）。感染患者住院的总体患病率为 10%（95%CI：7-12%）（I=95.6%，P<0.001）。住院患者死亡的总体患病率为 4%（95%CI：1-6%）（I=82.4%，P<0.001）。
结论
COVID-19 感染的多发性硬化症患者住院率较高，而总体感染率估计为 4%。
Zotero 插件